Saudi Pharmaceutical Industries and Medical Appliances Corporation (2070.SR)
SAR 31.65
(-0.32%)
SAR 31.65
(-0.32%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2.35 Billion SAR | 10.16% |
| 2022 | 2.13 Billion SAR | -12.37% |
| 2021 | 2.44 Billion SAR | -6.55% |
| 2020 | 2.61 Billion SAR | 4.3% |
| 2019 | 2.5 Billion SAR | -47.47% |
| 2018 | 4.76 Billion SAR | -0.05% |
| 2017 | 4.77 Billion SAR | -1.44% |
| 2016 | 4.83 Billion SAR | 341.2% |
| 2015 | 1.09 Billion SAR | 65.47% |
| 2014 | 662.93 Million SAR | 3.02% |
| 2013 | 643.47 Million SAR | 9.08% |
| 2012 | 589.91 Million SAR | 10.15% |
| 2011 | 535.56 Million SAR | 7.33% |
| 2010 | 499 Million SAR | -5.39% |
| 2009 | 527.42 Million SAR | 0.2% |
| 2008 | 526.39 Million SAR | 11.19% |
| 2007 | 473.41 Million SAR | 20.14% |
| 2006 | 394.04 Million SAR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 2.64 Billion SAR | 12.14% |
| 2024 Q2 | 2.78 Billion SAR | 5.36% |
| 2023 Q3 | 2.42 Billion SAR | -0.78% |
| 2023 Q2 | 2.44 Billion SAR | -1.49% |
| 2023 Q1 | 2.48 Billion SAR | 16.06% |
| 2023 Q4 | 2.35 Billion SAR | -2.89% |
| 2023 FY | 2.35 Billion SAR | 10.16% |
| 2022 Q4 | 2.13 Billion SAR | -9.32% |
| 2022 FY | 2.13 Billion SAR | -12.37% |
| 2022 Q1 | 2.52 Billion SAR | 3.39% |
| 2022 Q2 | 2.64 Billion SAR | 4.92% |
| 2022 Q3 | 2.35 Billion SAR | -10.92% |
| 2021 Q1 | 2.6 Billion SAR | -0.36% |
| 2021 FY | 2.44 Billion SAR | -6.55% |
| 2021 Q3 | 2.58 Billion SAR | 0.09% |
| 2021 Q4 | 2.44 Billion SAR | -5.65% |
| 2021 Q2 | 2.58 Billion SAR | -0.69% |
| 2020 Q4 | 2.61 Billion SAR | -45.04% |
| 2020 FY | 2.61 Billion SAR | 4.3% |
| 2020 Q2 | 4.75 Billion SAR | 6.49% |
| 2020 Q3 | 4.75 Billion SAR | -0.1% |
| 2020 Q1 | 4.46 Billion SAR | 78.38% |
| 2019 Q1 | 2.14 Billion SAR | -55.1% |
| 2019 FY | 2.5 Billion SAR | -47.47% |
| 2019 Q4 | 2.5 Billion SAR | -6.15% |
| 2019 Q3 | 2.66 Billion SAR | -48.57% |
| 2019 Q2 | 5.18 Billion SAR | 142.36% |
| 2018 Q1 | 5.12 Billion SAR | 7.42% |
| 2018 FY | 4.76 Billion SAR | -0.05% |
| 2018 Q2 | 5.2 Billion SAR | 1.54% |
| 2018 Q3 | 5.16 Billion SAR | -0.72% |
| 2018 Q4 | 4.76 Billion SAR | -7.7% |
| 2017 Q3 | 4.71 Billion SAR | 2.62% |
| 2017 Q1 | 4.73 Billion SAR | -2.21% |
| 2017 FY | 4.77 Billion SAR | -1.44% |
| 2017 Q4 | 4.77 Billion SAR | 1.24% |
| 2017 Q2 | 4.59 Billion SAR | -2.99% |
| 2016 Q3 | 1.96 Billion SAR | 11.94% |
| 2016 Q2 | 1.75 Billion SAR | 18.67% |
| 2016 Q1 | 1.47 Billion SAR | 34.76% |
| 2016 FY | 4.83 Billion SAR | 341.2% |
| 2016 Q4 | 4.83 Billion SAR | 146.45% |
| 2015 Q3 | 936.45 Million SAR | 42.96% |
| 2015 FY | 1.09 Billion SAR | 65.47% |
| 2015 Q4 | 1.09 Billion SAR | 17.14% |
| 2015 Q2 | 655.05 Million SAR | 14.03% |
| 2015 Q1 | 574.46 Million SAR | -13.34% |
| 2014 FY | 662.93 Million SAR | 3.02% |
| 2014 Q4 | 662.93 Million SAR | -4.7% |
| 2014 Q3 | 695.61 Million SAR | -0.44% |
| 2014 Q2 | 698.68 Million SAR | -7.8% |
| 2014 Q1 | 757.75 Million SAR | 17.76% |
| 2013 Q4 | 643.47 Million SAR | -10.78% |
| 2013 FY | 643.47 Million SAR | 9.08% |
| 2013 Q1 | 392.28 Million SAR | -33.5% |
| 2013 Q2 | 551.05 Million SAR | 40.47% |
| 2013 Q3 | 721.26 Million SAR | 30.89% |
| 2012 Q4 | 589.91 Million SAR | 44.96% |
| 2012 FY | 589.91 Million SAR | 10.15% |
| 2012 Q3 | 406.95 Million SAR | 0.0% |
| 2011 FY | 535.56 Million SAR | 7.33% |
| 2010 FY | 499 Million SAR | -5.39% |
| 2009 FY | 527.42 Million SAR | 0.2% |
| 2008 FY | 526.39 Million SAR | 11.19% |
| 2007 FY | 473.41 Million SAR | 20.14% |
| 2006 FY | 394.04 Million SAR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Jamjoom Pharmaceuticals Factory Company | 249.83 Million SAR | -843.016% |